Trial Profile
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Atorvastatin; Ezetimibe
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Acronyms ODYSSEY-Alternative
- Sponsors Regeneron Pharmaceuticals
- 28 Aug 2023 Results (n=153) assessing safety of alirocumab for paediatric patients with heterozygous familial hypercholesterolaemia (HeFH) inadequately controlled with statins presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
- 14 Nov 2018 Results of an open-label extension trial (OLE) of ODYSSEY-Alternative assessing long-term safety experience with alirocumab presented at the 91st Annual Scientific Sessions of the American Heart Association
- 05 Sep 2018 Results published in the Diabetic Medicine